Literature DB >> 3373285

Significance of "ultra-early" rebleeding in subarachnoid hemorrhage.

J Hillman1, C von Essen, W Leszniewski, I Johansson.   

Abstract

Knowledge of the local incidence of aneurysm rupture permits the conclusion that almost every patient in the population of 933,800 persons served by the authors' institution who was stricken by this catastrophe and survived long enough to be transported was treated at this center (121 patients during 34 months). Of these, 9.1% were admitted late (greater than 72 hours after subarachnoid hemorrhage (SAH]; of the remaining cases, 94.5% were seen within 24 hours and 50% within 6 hours post-SAH. Of the 121 patients, 10% were neurologically devastated on arrival, a late operation was planned for 19%, and the earliest possible surgery and nimodipine administration was selected for 71%. In this latter group, 50% of the operations were begun within 24 hours and 76% within 48 hours post-SAH. Sixty percent of all mortality and morbidity could be linked to the initial aneurysm bleed. The remaining 40% could be ascribed to potentially avoidable causes of unfavorable outcome. No less than 9.6% of all patients admitted within 24 hours after SAH suffered from "ultra-early" rebleeding during transportation or preparation for operation. The mortality rate from such rebleeding was 7.4%, compared with the 9.1% combined mortality rate from complications and late ischemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373285     DOI: 10.3171/jns.1988.68.6.0901

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

Review 1.  Rebleeding after aneurysmal subarachnoid hemorrhage.

Authors:  R M Starke; E S Connolly
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

2.  Selective angiography for early aneurysm detection in acute subarachnoid haemorrhage.

Authors:  J Hillman
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

3.  Effect of ultra-early referral on management outcome in subarachnoid haemorrhage.

Authors:  T Inagawa
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  The notion of "warning leaks" in subarachnoid haemorrhage: are such patients in fact admitted with a rebleed?

Authors:  F H Linn; G J Rinkel; A Algra; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 5.  The importance of early brain injury after subarachnoid hemorrhage.

Authors:  Fatima A Sehba; Jack Hou; Ryszard M Pluta; John H Zhang
Journal:  Prog Neurobiol       Date:  2012-03-10       Impact factor: 11.685

6.  Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States.

Authors:  Adnan I Qureshi; Mustapha A Ezzeddine; Abu Nasar; M Fareed K Suri; Jawad F Kirmani; Haitham M Hussein; Afshin A Divani; Alluru S Reddi
Journal:  Am J Emerg Med       Date:  2007-01       Impact factor: 2.469

7.  High re-bleeding rate in young adults after subarachnoid haemorrhage from giant aneurysms.

Authors:  Ralf Dirk Rothoerl; Thomas Finkenzeller; Thomas Schubert; Chris Woertgen; Alexander Brawanski
Journal:  Neurosurg Rev       Date:  2005-10-12       Impact factor: 3.042

8.  Cerebral vasospasm after subarachnoid haemorrhage of unknown aetiology: a clinical and transcranial Doppler study.

Authors:  C Schaller; B Raueiser; V Rohde; W Hassler
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 9.  Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.

Authors:  Mark Chwajol; Robert M Starke; Grace H Kim; Stephan A Mayer; E Sander Connolly
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

10.  Current pattern of in-hospital aneurysmal rebleeds. Analysis of a series treated with individually timed surgery and intravenous nimodipine.

Authors:  H J Steiger; J Fritschi; R W Seiler
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.